 Mustang Bio Inc NASDAQ: MBIO and the City of Hope, an independent cancer research and treatment center, have dosed the first patient in Phase 1 trial evaluating MB-101 in patients with leptomeningeal brain tumors. The trial will enroll up to 30 patients and determine the safety and feasibility of administering MB-101 through the ICV Rickham catheter over four weekly cycles in patients with glioblastoma Arm 1 and ependymoma or medulloblastoma Arm 2. 